Novel Antifibrotic Designated Breakthrough Therapy for Progressive Pulmonary Fibrosis
The FDA has granted Breakthrough Therapy designation to BMS-986278, an investigational LPA1 antagonist, for progressive pulmonary fibrosis.
Stay updated with breaking news from Neuroscience Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted Breakthrough Therapy designation to BMS-986278, an investigational LPA1 antagonist, for progressive pulmonary fibrosis.
Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any...
New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the company's steadfast dedication to tackling cardiovascular diseases ...
(BPT) - Kim Pfleeger was ready. Clad in gym clothes, she leaned against the wall outside the locker room, eager to return to the basketball court. Her dad, Randy, would
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 24, 2022 /PRNewswire/ -- The Global psychedelic drugs market has been steadily rising for the past few years and is projected